Gamma-glutamyltransferase is associated with cardiovascular and all-cause mortality: A meta-analysis of prospective cohort studies

Preventive Medicine

Volumn 57, Issue 1, 2013, Pages 31-37

  Du, Guangli ^a   Song, Ziyu ^b   Zhang, Qin ^b  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Shanghai Changning Center Hospital   (China)

Author keywords

All cause mortality; Cardiovascular mortality; Gamma glutamyltransferase; Meta analysis

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE;

ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR MORTALITY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; LIVER FUNCTION; META ANALYSIS; METABOLIC SYNDROME X; PRIORITY JOURNAL; QUALITY CONTROL; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK; SAMPLE SIZE; YOUNG ADULT;

EID: 84878633282     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2013.03.011     Document Type: Article

References (45)

1. Aksakal E., Tanboga I.H., Kurt M. The relation of serum gamma-glutamyl transferase levels with coronary lesion complexity and long-term outcome in patients with stable coronary artery disease. Atherosclerosis 2012, 221:596-601.
2. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
3. Breitling L.P., Grandi N.C., Hahmann H., Wusten B., Rothenbacher D., Brenner H. Gamma-glutamyltransferase and prognosis in patients with stable coronary heart disease followed over 8years. Atherosclerosis 2010, 210:649-655.
4. Brenner H., Rothenbacher D., Arndt V., Schuberth S., Fraisse E., Fliedner T.M. Distribution, determinants, and prognostic value of gamma-glutamyltransferase for all-cause mortality in a cohort of construction workers from southern Germany. Prev. Med. 1997, 26:305-310.
5. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
6. Costanzo S., Di Castelnuovo A., Donati M.B., Iacoviello L., de Gaetano G. Alcohol consumption and mortality in patients with cardiovascular disease: a meta-analysis. J. Am. Coll. Cardiol. 2010, 55:1339-1347.
7. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
8. Dogan A., Icli A., Aksoy F., et al. Gamma-glutamyltransferase in acute coronary syndrome patients without ST elevation and its association with stenotic lesion and cardiac events. Coron. Artery Dis. 2012, 23:39-44.
9. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
10. Emdin M., Pompella A., Paolicchi A. Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation 2005, 112:2078-2080.
11. Emdin M., Passino C., Franzini M., Paolicchi A., Pompella A. Gamma-glutamyltransferase and pathogenesis of cardiovascular diseases. Future Cardiol. 2007, 3:263-270.
12. Fan J.G., Zhu J., Li X.J., et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J. Hepatol. 2005, 43:508-514.
13. Fraser A., Harris R., Sattar N., Ebrahim S., Smith G.D., Lawlor D.A. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health study and meta-analysis. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2729-2735.
14. Haring R., Wallaschofski H., Nauck M., Dorr M., Baumeister S.E., Volzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009, 50:1403-1411.
15. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
16. Hozawa A., Okamura T., Kadowaki T., et al. Gamma-glutamyltransferase predicts cardiovascular death among Japanese women. Atherosclerosis 2007, 194:498-504.
17. Hurjui D.M., Nita O., Graur L.I., et al. Non-alcoholic fatty liver disease is associated with cardiovascular risk factors of metabolic syndrome. Rev. Med. Chir. Soc. Med. Nat. Iasi 2012, 116:692-699.
18. Kengne A.P., Czernichow S., Stamatakis E., Hamer M., Batty G.D. Gamma-glutamyltransferase and risk of cardiovascular disease mortality in people with and without diabetes: pooling of three British health surveys. J. Hepatol. 2012, 57:1083-1089.
19. Lee D.H., Jacobs D.R., Gross M., et al. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Clin. Chem. 2003, 49:1358-1366.
20. Lee D.H., Silventoinen K., Hu G., et al. Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur. Heart J. 2006, 27:2170-2176.
21. Lee D.S., Evans J.C., Robins S.J., et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart study. Arterioscler. Thromb. Vasc. Biol. 2007, 27:127-133.
22. Lee D.H., Buijsse B., Steffen L., Holtzman J., Luepker R., Jacobs D.R. Association between serum gamma-glutamyltransferase and cardiovascular mortality varies by age: the Minnesota Heart Survey. Eur. J. Cardiovasc. Prev. Rehabil. 2009, 16:16-20.
23. Lioudaki E., Ganotakis E.S., Mikhailidis D.P. Liver enzymes: potential cardiovascular risk markers?. Curr. Pharm. Des. 2011, 17:3632-3643.
24. Liu C.F., Zhou W.N., Fang N.Y. Gamma-glutamyltransferase levels and risk of metabolic syndrome: a meta-analysis of prospective cohort studies. Int. J. Clin. Pract. 2012, 66:692-698.
25. Mason J.E., Starke R.D., Van Kirk J.E. Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. Prev. Cardiol. 2010, 13:36-41.
26. Meisinger C., Doring A., Schneider A., Lowel H. Serum gamma-glutamyltransferase is a predictor of incident coronary events in apparently healthy men from the general population. Atherosclerosis 2006, 189:297-302.
27. Monami M., Bardini G., Lamanna C., et al. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism 2008, 57:387-392.
28. Park S.H., Jeon W.K., Kim S.H., et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J. Gastroenterol. Hepatol. 2006, 21:138-143.
29. Rahman I., MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur. Respir. J. 2000, 16:534-554.
30. Ratziu V., Bellentani S., Cortez-Pinto H., Day C., Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 2010, 53:372-384.
31. Rollason J.G., Pincherle G., Robinson D. Serum gamma glutamyl transpeptidase in relation to alcohol consumption. Clin. Chim. Acta 1972, 39:75-80.
32. Ruhl C.E., Everhart J.E. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009, 136(477-85):e11.
33. Ruttmann E., Brant L.J., Concin H., Diem G., Rapp K., Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005, 112:2130-2137.
34. Shin J.Y., Chang S.J., Shin Y.G., Seo K.S., Chung C.H. Elevated serum gamma-glutamyltransferase levels are independently associated with insulin resistance in non-diabetic subjects. Diabetes Res. Clin. Pract. 2009, 84:152-157.
35. Sluik D., Beulens J.W., Weikert C., et al. Gamma-glutamyltransferase, cardiovascular disease and mortality in individuals with diabetes mellitus. Diabetes Metab. Res. Rev. 2012, 28:284-288.
36. Stojakovic T., Scharnagl H., Trauner M., et al. Serum gamma-glutamyl transferase and mortality in persons undergoing coronary angiography-the Ludwigshafen Risk and Cardiovascular Health study. Atherosclerosis 2010, 208:564-571.
37. Strasak A.M., Kelleher C.C., Klenk J., et al. Longitudinal change in serum gamma-glutamyltransferase and cardiovascular disease mortality: a prospective population-based study in 76,113 Austrian adults. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1857-1865.
38. Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
39. Targher G. Elevated serum gamma-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer-a narrative review. Clin. Chem. Lab. Med. 2010, 48:147-157.
40. Targher G., Byrne C.D. Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J. Clin. Endocrinol. Metab. 2013, 98:483-495.
41. Turgut O., Tandogan I., Gurlek A. Association of gamma-glutamyltransferase with cardiovascular risk: a prognostic outlook. Arch. Med. Res. 2009, 40:318-320.
42. Verrijken A., Francque S., Mertens I., Talloen M., Peiffer F., Van Gaal L. Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients. Int. J. Obes. (Lond.) 2010, 34:899-907.
43. Wannamethee G., Ebrahim S., Shaper A.G. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am. J. Epidemiol. 1995, 142:699-708.
44. Wannamethee S.G., Lennon L., Shaper A.G. The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. Atherosclerosis 2008, 201:168-175.
45. Whitfield J.B. Gamma glutamyl transferase. Crit. Rev. Clin. Lab. Sci. 2001, 38:263-355.